company background image
PLRX

Pliant Therapeutics NasdaqGS:PLRX Stock Report

Last Price

US$17.18

Market Cap

US$837.7m

7D

-12.0%

1Y

24.5%

Updated

07 Dec, 2022

Data

Company Financials +
PLRX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PLRX Stock Overview

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.

Pliant Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pliant Therapeutics
Historical stock prices
Current Share PriceUS$17.18
52 Week HighUS$26.25
52 Week LowUS$3.97
Beta1.08
1 Month Change-23.37%
3 Month Change-14.44%
1 Year Change24.49%
3 Year Changen/a
5 Year Changen/a
Change since IPO-19.34%

Recent News & Updates

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Recent updates

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17
Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22
Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21
We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Dec 17
Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Shareholder Returns

PLRXUS PharmaceuticalsUS Market
7D-12.0%0.5%-0.4%
1Y24.5%13.2%-20.6%

Return vs Industry: PLRX exceeded the US Pharmaceuticals industry which returned 15% over the past year.

Return vs Market: PLRX exceeded the US Market which returned -17.6% over the past year.

Price Volatility

Is PLRX's price volatile compared to industry and market?
PLRX volatility
PLRX Average Weekly Movement7.8%
Pharmaceuticals Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: PLRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PLRX's weekly volatility has decreased from 25% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015114Bernard Couliehttps://pliantrx.com

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis.

Pliant Therapeutics, Inc. Fundamentals Summary

How do Pliant Therapeutics's earnings and revenue compare to its market cap?
PLRX fundamental statistics
Market CapUS$837.69m
Earnings (TTM)-US$112.79m
Revenue (TTM)US$9.72m

86.2x

P/S Ratio

-7.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PLRX income statement (TTM)
RevenueUS$9.72m
Cost of RevenueUS$0
Gross ProfitUS$9.72m
Other ExpensesUS$122.51m
Earnings-US$112.79m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.31
Gross Margin100.00%
Net Profit Margin-1,160.53%
Debt/Equity Ratio2.9%

How did PLRX perform over the long term?

See historical performance and comparison